Re-EValuating the Inhibition of Stress Erosions (REVISE) - COVID-19 Cohort Study
Trial Summary
What is the purpose of this trial?
Commonly employed medications used in critically ill patients requiring life support include proton pump inhibitors (PPIs). These medications are thought to prevent gastrointestinal (GI) bleeding from stress-induced ulceration. Despite their widespread use, they do hold some risks which include infection in the form of pneumonia and diarrheal illnesses such as Clostridioides difficile infection (C. difficile). Emerging high-quality studies suggest PPI usage does not influence susceptibility to COVID-19 infection, however some studies suggest PPI use leads to poor outcomes in this population, including prolonged time on life-support and death. While we can appreciate the negative effects of PPI may be magnified in the sickest of patients, namely hospitalized patients with COVID-19, the beneficial or potentially harmful role they play in this population remains unclear. We aim to build a clinical profile to further describe critically ill patients with COVID-19 in Ontario using the infrastructure of an ongoing multicenter clinical trial of acid suppression. We will identify characteristics that predict poor outcomes among sick COVID patients, examining the impact of PPIs on this population.
Research Team
Deborah Cook, MD
Principal Investigator
McMaster University
Brittany Dennis, MD
Principal Investigator
McMaster University
Eligibility Criteria
Inclusion Criteria
Treatment Details
Interventions
- PPIs (Proton Pump Inhibitor)
Find a Clinic Near You
Who Is Running the Clinical Trial?
McMaster University
Lead Sponsor
Evan Stein
McMaster University
Chief Medical Officer since 2015
MD, PhD
Sam
McMaster University
Chief Executive Officer since 2023
MBA from McMaster University
Canadian Institutes of Health Research (CIHR)
Collaborator
Dr. Paul C. Hébert
Canadian Institutes of Health Research (CIHR)
Chief Executive Officer
MD, University of Ottawa
Dr. Paul C. Hébert
Canadian Institutes of Health Research (CIHR)
Chief Medical Officer
MD, University of Ottawa
The Physicians' Services Incorporated Foundation
Collaborator
Dr. Andrew Pickersgill
The Physicians' Services Incorporated Foundation
Chief Executive Officer since 2017
MD from Harvard Medical School
Dr. Stephanie Bloomfield
The Physicians' Services Incorporated Foundation
Chief Medical Officer since 2017
MD from University of Toronto